Compare Bristol-Myers Squibb Co (BMY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sony Group Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.67 (market cap $116.30B), while Sony Group Corp trades at $20.84 (market cap $122.79B). The key difference: Bristol-Myers Squibb Co and Sony Group Corp are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SONY | |
|---|---|---|
Market Cap | $116.30B | $122.79B |
Sector | Health | Technology |
52-Week High | $62.37 | $30.26 |
52-Week Low | $42.60 | $19.32 |
Enterprise Value | $152.24B | $119.28B |
Dividend Yield | 4.42% | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Sony trades at $20.68, down 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong operating cash flow of $2.32 trillion for 2025 and maintains solid valuation metrics including a P/E of 19.51. Recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook remains mixed with analyst consensus strongly bullish (69% buy ratings) but near-term earnings volatility. Key opportunities include digital transformation and financial services expansion, while risks involve execution of digital strategy and projected net income decline to -$326.9 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
